MedTrace Logo

Utility of Immediate Post Placental Insertion of Intrauterine Device During Cesarean Delivery

NCT04136613 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2020-01-18

No results posted yet for this study

Summary

Iraq is a country that ranks 33rd around world population growth rate. Meanwhile it is one of the counties in the middle east with the highest fertility rate, In addition to the considerable number of unintended pregnancy mainly in postpartum period.

The less use of family planning methods, the higher the fertility rate and the less interpregnancy interval which will carry an obvious more risk to the mother and the fetus especially if the cesarean delivery rate shown an increase trend as the case in Iraq. For that reason, contraception needs to be practiced in this critical period and an intrauterine contraceptive device ( IUD), the most commonly used reversible method of contraception worldwide could be an excellent choice during this period.

There were few evidences available about the safety and feasibility on practicing this type of contraception when we did start three years ago and no previous evidences in Iraq about practicing this method at the immediate postpartum period.

Conditions

  • Contraception Behavior

Interventions

DEVICE

Copper Intra uterine contarceptive device ( Cu-T 380A)

Insertion of the Cu-T 380A during cesarean delivery immediately after placental removal.

Sponsors & Collaborators

  • Elweyia Maternity Teaching Hospital

    collaborator OTHER

  • Taghreed Alhaidari

    lead OTHER

Principal Investigators

  • Taghreed K Alhaidari, CABOG · Al Kindy College of Medicine, University of Baghdad

  • Taghreed K Alhaidari, CABOG · Al Kindy College of Medicine, University of Baghdad

  • Asmaa T Majeed, FICOG · Al Kindy College of Medicine, University of Baghdad

  • Sahar J Al-Jassani, CABOG · Al Kindy College of Medicine, University of Baghdad

  • Hayder A Fawzi, FICMS · Department of Pharmacy, Al-Esraa University College

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-01
Primary Completion
2019-01-01
Completion
2019-06-01

Countries

  • Iraq

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04136613 on ClinicalTrials.gov